A Case of Decreased Milk Production Associated With Aripiprazole

To the Editor: Aripiprazole is a second-generation antipsychotic medication that can be used in the management of major depression and other disorders that commonly arise during the postpartum period. Due to its partial agonistic action at the D2 receptor, aripiprazole has been used to treat hyperprolactinemia in patients on D2 antagonists. Higher doses of aripiprazole (15–30 mg) can decrease antipsychotic-induced hyperprolactinemia. Yasui-Furukori et al reported this effect with a low dose (3 mg/d) of aripiprazole, and the effect plateaued at doses beyond 6 mg/d. However, little is known about the effect of aripiprazole on milk production in lactating postpartum patients. This report is of unexpected decrease in milk production after initiation of aripiprazole, with restoration of milk production after discontinuation of the drug.

Case report. A 40-year-old African American mother of 4 presented to our partial hospital program 5 weeks postpartum reporting depression, mood swings, anxiety, and panic attacks. She also endorsed poor sleep, increased energy, and hyperverbal speech occurring a week prior to presentation. She had a history of anxiety. Several years ago, she had 5- to 7-day periods with little or no sleep, distractibility, increased energy, grandiosity, and risky behaviors including shoplifting; however, she was using alcohol, cocaine, marijuana, and diet and energy pills at that time.

Working diagnoses according to DSM-5 were unspecified bipolar disorder and generalized anxiety disorder with panic attacks. The patient was taking milk thistle and fenugreek supplements at the time of admission. Risperidone and hydroxyzine were recommended. The patient started hydroxyzine 50 mg but not risperidone due to concerns about sedation. She had no decrease in milk production when she was taking hydroxyzine alone for 3–5 days. Aripiprazole 5 mg was then added in lieu of risperidone. The patient reported decreased milk production after 5 days on both aripiprazole and hydroxyzine, to the point that she was forced to supplement with formula. Milk production normalized less than 9 days after stopping both hydroxyzine and aripiprazole. At follow-up, other medication options were discussed; she elected not to use psychotropics. She continued the milk thistle and fenugreek supplements.

The adverse event of decreased milk production appeared after aripiprazole was administered, and it improved when the drug was discontinued (Naranjo Scale score of 2). While we are unaware of any published reports of hydroxyzine’s suppressing lactation, anticholinergic medications may decrease lactation. Mendhekar et al describe a case of aripiprazole-induced lactation suppression. There is a potentially conflicting report of aripiprazole-induced hyperprolactinemia and galactorrhea in a young nonlactating female. Psychogenic factors might also affect milk production.

The present case suggests aripiprazole may possibly decrease milk production in lactating women. This factor could be important in informed consent discussions when considering aripiprazole for nursing mothers.

References


Russell Yskes, MD
Robi Thomas, PhD, RN, PMHNP-BC
Madhavi-Latha Nagalla, MD

© 2018 Copyright Physicians Postgraduate Press, Inc.